| abstract |
The invention relates to the field of pharmaceuticals, more specifically to the treatment and / or prevention of HIV infection. The claimed set of drugs consisting of (1S, 4R) -cis-4- [2-amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopenten-1-methanol and (2R, cis) - 4-amino- (2-hydroxymethyl-1,3-oxathiolan-5-yl) - (1H) -pyrimidin-2-one or (2R, cis) -4-amino-5-fluoro-1- (2-hydroxymethyl -1,3-oxathiolan-5-yl) (1H) -pyrimidin-2-one, or their physiologically acceptable functional derivatives. In addition, the invention relates to a pharmaceutical preparation consisting of (1S, 4R) -cis-4- [2-amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopenten-1-methanol and ( 2R, cis) -4-amino-1- (2-hydroxymethyl-1,3-oxathiolan-5-yl) - (1H) -pyrimidin-2-one in combination with one or more pharmaceutically acceptable carriers, as well as a method for treating or preventing the symptoms or effects of HIV infection in an infected animal, using the said kit and pharmaceutical preparation. The use of (1S, 4R) -cis-4- [2-amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopenten-1-methanol is also described, either simultaneously or sequentially with a) zidovudine and (2R, cis) -4-amino-1- (2-hydroxymethyl-1,3-oxathiolan-5-yl) - (1H) -pyrimidin-2-one or b) zidovudine and (2R, cis) -4- amino-5-fluoro-1- (2-hydroxymethyl-1,3-oxathiolan-5-yl) - (1H) -pyrimidin-2-one, and the use of a set of drugs, including combinations of these compounds, in the manufacture of a drug for treating and / or HIV prevention. |